-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head-To-Head Review: Agilon Health (NYSE:AGL) and Lisata Therapeutics (NASDAQ:LSTA)
Head-To-Head Review: Agilon Health (NYSE:AGL) and Lisata Therapeutics (NASDAQ:LSTA)
agilon health (NYSE:AGL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Institutional & Insider Ownership
6.0% of Lisata Therapeutics shares are held by institutional investors. 3.3% of agilon health shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Get agilon health alerts:Profitability
This table compares agilon health and Lisata Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
agilon health | -4.30% | -9.31% | -5.72% |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
Valuation and Earnings
This table compares agilon health and Lisata Therapeutics' top-line revenue, earnings per share (EPS) and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
agilon health | $1.83 billion | 3.66 | -$406.49 million | ($0.26) | -62.62 |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.20 |
Lisata Therapeutics has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
agilon health has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and target prices for agilon health and Lisata Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
agilon health | 0 | 1 | 7 | 0 | 2.88 |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
agilon health presently has a consensus target price of $28.38, suggesting a potential upside of 74.29%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than agilon health.
Summary
Lisata Therapeutics beats agilon health on 7 of the 13 factors compared between the two stocks.
About agilon health
(Get Rating)
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.
agilon health (NYSE:AGL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Agilon Health(纽约证券交易所代码:AGL-GET Rating)和李萨塔治疗公司(Lyata Treateutics:LSTA-GET Rating)都是医疗公司,但哪种投资更好?我们将根据两家公司的收益、估值、机构所有权、风险、盈利能力、分析师建议和股息等方面的实力进行比较。
Institutional & Insider Ownership
机构与内部人持股
6.0% of Lisata Therapeutics shares are held by institutional investors. 3.3% of agilon health shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
李萨塔治疗公司6.0%的股份由机构投资者持有。Agilon Health 3.3%的股份由内部人士持有。相比之下,李萨塔治疗公司2.2%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一家公司有望实现长期增长。
Profitability
盈利能力
This table compares agilon health and Lisata Therapeutics' net margins, return on equity and return on assets.
此表比较了Agilon Health和Lisata Treeutics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
agilon health | -4.30% | -9.31% | -5.72% |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
净利润率 | 股本回报率 | 资产回报率 | |
雅居隆健康 | -4.30% | -9.31% | -5.72% |
利萨塔治疗公司 | 不适用 | -29.53% | -27.96% |
Valuation and Earnings
估值和收益
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
agilon health | $1.83 billion | 3.66 | -$406.49 million | ($0.26) | -62.62 |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.20 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
雅居隆健康 | 18.3亿美元 | 3.66 | -4.0649亿美元 | ($0.26) | -62.62 |
利萨塔治疗公司 | 不适用 | 不适用 | -2,747万元 | ($12.23) | -0.20 |
Lisata Therapeutics has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
利萨塔治疗公司的收入低于Agilon Health,但收入高于Agilon Health。Agilon Health的市盈率低于李萨塔治疗公司,这表明它目前是两只股票中更负担得起的一只。
Risk & Volatility
风险与波动性
agilon health has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Agilon Health的贝塔系数为0.78,表明其股价的波动性比标准普尔500指数低22%。相比之下,李萨塔治疗公司的贝塔指数为0.97,这表明其股价的波动性比标准普尔500指数低3%。
Analyst Recommendations
分析师建议
This is a summary of current ratings and target prices for agilon health and Lisata Therapeutics, as provided by MarketBeat.
这是由MarketBeat提供的Agilon Health和Lisata Treeutics的当前评级和目标价格的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
agilon health | 0 | 1 | 7 | 0 | 2.88 |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
雅居隆健康 | 0 | 1 | 7 | 0 | 2.88 |
利萨塔治疗公司 | 0 | 0 | 2 | 0 | 3.00 |
agilon health presently has a consensus target price of $28.38, suggesting a potential upside of 74.29%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than agilon health.
Agilon Health目前的共识目标价为28.38美元,暗示潜在涨幅为74.29%。利萨塔治疗公司的共识目标价为15美元,暗示潜在上涨500.00%。鉴于李萨塔治疗公司更强的共识评级和更高的可能上行空间,分析师显然认为利萨塔治疗公司比阿吉隆健康公司更有利。
Summary
摘要
Lisata Therapeutics beats agilon health on 7 of the 13 factors compared between the two stocks.
在两只股票之间的13个因素中,李萨塔治疗公司在7个因素上击败了Agilon Health。
About agilon health
关于阿吉隆健康
(Get Rating)
(获取评级)
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Agilon Health,Inc.通过美国社区的初级保健医生为老年人提供医疗服务。截至2021年12月31日,它为大约23.8万名高级成员提供服务,其中包括18.63万名联邦医疗保险优势成员和5.17万名联邦医疗保险按服务收费受益人。该公司前身为Agilon Health Topco,Inc.,于2021年3月更名为Agilon Health,Inc.。Agilon Health,Inc.成立于2016年,总部设在德克萨斯州奥斯汀。
About Lisata Therapeutics
关于李萨塔治疗公司
(Get Rating)
(获取评级)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
利萨塔治疗公司是一家临床阶段的生物制药公司,专注于开发细胞疗法并将其商业化,以逆转疾病和/或促进受损组织的再生。它的候选产品包括接受Sakigake指定的HONEDRA,用于治疗严重肢体缺血的第二阶段临床试验;XOWNA,用于治疗冠状动脉微血管功能障碍的第二阶段临床试验;以及CLBS201,一种用于治疗慢性肾脏疾病透析前患者的CD34+细胞疗法。该公司前身为NeoStem,Inc.,并于2015年6月更名为Caladrius Biosciences,Inc.。该公司前身为Caladrius Biosciences,Inc.,并于2022年9月15日更名为李萨塔治疗公司。利萨塔治疗公司成立于1980年,总部设在新泽西州的巴斯金里奇。
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.
获得《雅居伦健康日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Agilon Health及相关公司评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧